Schaut mal ins Biotech-Board. Heisse Meldung!!! - 500 Beiträge pro Seite

[ChrisHamburg]

Firma hat angeblich Meldung gegen AIDS entdeckt.

[HansF]

Wer kann mir weiterhelfen mit Synsorb. Geht die ganze Woche rauf und runter. Soll ich halten oder verkaufen?????

[boxenstopp]

Wenn alles glattläuft Kursziel 1000.......


www.imnr.com


DSMB/Interim Analysis


The first interim analysis meeting for the Remune study in Thailand, Protocol 2101B, was completed on Saturday,13 March
1999. The DSMB reported that the study is going well and has a very high probability of success. The study will continue until
completion of all 297 volunteers up to Week 40. In the interim, Dr Vina Churdboonchart, the Principal Investigator will submit an
application to the Thai FDA for the registration of Remune in Thailand.

Strong Buy

[ciceros Revenge]

Hallo,
das Kursziel vo 1000 Euro ist im Augenblick wohl etwas übertrieben. Allerdings möchte ich einräumen, daß kurzfristig noch sicherlich 30-40% drin sind. Bei einem nachweisbaren Erfolg gäbe es absolut kein Halten mehr... !!! Ich werde morgen früh versuchen noch 500 Stücke mit dem Limit 22 Euro zu bekommen, vielleicht habe ich ja noch ein bißchen Glück! Vorsicht beim Neuen Markt erst ab ca. 11Uhr kaufen, um die Richtung dessen einigermaßen einschätzen zu können!
Gute Nacht.


cicero

[Jockele]

an ciceros
das sich bei ws 80% traumtänzer tummeln habe ich geschluckt.
aber warum willst du für 22E 500Stck. Synsorb kaufen wenn der kurs bei 6,8 liegt. vielleicht hast du irgendetwas verwechselt.
wenn nicht ich habe 10.000stck. die kann ich dir für 11E abtretten.
(ist ein spaß) schlaf gut.

nette grüße

jockele

[galadriel1]

NEUER BERICHT zu Immune Respone. SUPER !!!


Quelle bloomberg.com imnr

usa 23.3.2000 nach börsenschluß


Immune Response Shares Rise on AIDS Drug Study (Update1)
By Brian Reid
Immune Response Shares Rise on AIDS Drug Study (Update1)

(Closes shares, add details on FDA approval process in third
paragraph and HIV rate in Thailand in fifth paragraph.)

Carlsbad, California, March 23 (Bloomberg) -- Shares in
Immune Response Corp rose 43 percent after the company said
results of a study of its lead AIDS drug, Remune, conducted in
Thailand, could lead to government approval there.

Shares in the biotechnology company rose 4 11/16 to close at
15 11/16 in Nasdaq Stock Market trading. Last May, the stock
dropped 43 percent in two days, after a U.S. study of 2,500
patients found that Remune didn`t show any clinical benefit when
added to traditional combination AIDS therapy.

If Thailand`s Ministry of Public Health approves the drug,
which boosts the immune system of patients with HIV, it would
bring the money-losing company its first revenue. Such an approval
may be raising hopes for approval of the drug in the U.S., an
analyst said.
``People are saying, `Look, this is the first time the
company could get revenue. If this is approvable in Thailand,
maybe the chances of approval in the U.S. are higher than I
thought,` `` said Alan Auerbach, an analyst at First Security Van
Casper.

Still, the company is unlikely to submit the Thai data to
U.S. regulators.

More than 800,000 people in Thailand -- about 2.3 percent of
nation`s population -- have HIV, according to the World Health
Organization.

Patients taking only Remune in the study had a significantly
higher number of helper T cells in the blood, which may signal
immune system strength, according to a 297-person study presented
today at a medical meeting in Thailand,

In addition, researchers measured the level of HIV in the
bloodstream of 68 patients and found that 39 had no change in
their HIV level, while 20 people had reduced amounts of HIV in the
bloodstream and nine patients saw their HIV levels rise.
``This is particularly important for HIV patients who do not
have access to antiviral drug therapy,`` said Vina Churdboonchart,
the primary investigator on the trial. Churdboonchart said those
results were good enough to ask Thailand`s government to approve
Remune for sale in Thailand. The four injections a year of Remune
are less complicated and could turn out to be less expensive than
traditional AIDS therapy.

Carlsbad, California-based Immune Response is working with
Warner-Lambert Co. to test the drug in the U.S. The two companies
have initiated another large-scale clinical trial to see if Remune
can suppress HIV levels in patients after they stop taking
traditional AIDS drugs.

[eiswuerfel]

1000 e Kursziel; ne is klar